All In Biotech

Free tool

FAERS Monitor: Tascenso Odt

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214962 or its brand name (Tascenso Odt, Fingolimod Lauryl Sulfate). Reports on generic versions are filed under their own applications.

Reports

218

Serious

64

29% of reports

Hospitalization

21

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • heart rate decreased28
  • fatigue25
  • headache21
  • dizziness15
  • somnolence12
  • multiple sclerosis relapse11
  • gait disturbance8
  • nausea8
  • asthenia7
  • drug ineffective7
  • hypertension7
  • hospitalisation6
  • off label use6
  • abdominal pain upper5
  • fall5

Reports by year received

View as table
YearReports
202373
202488
202544
202613

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,941 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
heart rate decreasedSignal2877.054.52,026
multiple sclerosis relapseSignal1115.58.7135
somnolenceSignal125.83.343
gait disturbanceSignal84.02.015
hospitalisationSignal63.81.710
headacheSignal213.22.231
hypertensionSignal73.21.59
fatigueSignal253.12.135
dizzinessSignal152.91.817
abdominal pain upper52.31.03
asthenia71.80.92
fall51.40.60
nausea81.00.50
off label use60.70.31
drug ineffective70.50.23

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.